4-甲基戊烷酰肼 | 140157-44-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-甲基戊烷酰肼
• 英文名称: 4-methylpentanehydrazide
• 英文别名: 4-methyl-valeric acid hydrazide；4-Methyl-valeriansaeure-hydrazid；4-methyl-pentanoic acid hydrazide；4-methylpentanoyl hydrazide
• CAS: 140157-44-4
• 化学式: C₆H₁₄N₂O
• mdl: MFCD08061565
• 分子量: 130.19
• InChiKey: VOBMACGBVNTRGF-UHFFFAOYSA-N

物化性质

• 沸点：
  264.7±9.0 °C(Predicted)
• 密度：
  0.946±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  4-甲基戊烷酰肼 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Curtius, Journal fur praktische Chemie (Leipzig 1954), 1930, vol. <2>125, p. 185

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基-戊酸甲酯 在 肼 作用下， 以 乙醇 、 水 为溶剂， 以89%的产率得到4-甲基戊烷酰肼
  参考文献：
  名称：

  发现15-脂氧合酶-1药物样抑制剂的组合方法

  摘要：

  人15-脂氧合酶-1（15-LOX-1）是一种哺乳动物的脂氧合酶，在多种中枢神经系统和炎症性肺疾病中起着重要的调节作用。为了进一步探索这种酶在药物发现中的作用，需要具有良好的理化性质的新型有效抑制剂。为了鉴定此类新抑制剂，我们建立了一种基于酰基hydr化学的组合筛选方法。这代表了组合化学的一种新应用，其重点是理化性质的提高，而不是效力的提高。这种策略使我们能够有效地筛选出44种不同酰肼的反应混合物和我们先前报道的吲哚醛核心结构，而无需单独合成所有可能的结构单元组合。我们的方法为IC提供了三种新型抑制剂在纳摩尔范围内具有50个值，并改善了亲脂性配体效率。

  DOI：

  10.1016/j.ejmech.2019.04.021

文献信息

• Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives
  申请人：Buettelmann Bernd

  公开号：US20070082890A1

  公开（公告）日：2007-04-12

  The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein the definition of substituents is described in the claims. This class of compounds shows high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as a cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及以下式的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮䓬啉衍生物，其中取代基的定义在权利要求中描述。这类化合物对GABA A α5受体结合位点表现出高亲和力和选择性，可能有助于作为认知增强剂或治疗认知障碍如阿尔茨海默病的药物。
• Methods of treating diseases and disorders by targeting multiple kinases
  申请人：Narla Rama Krishna

  公开号：US20050107386A1

  公开（公告）日：2005-05-19

  The present invention is directed to the use of single agents, which are compounds that target two or more kinases simultaneously, thus substantially avoiding resistance to therapy. The invention provides methods for the use for, administration to, and treatment of individuals having a variety of diseases or conditions associated with the activity of two or more kinases, comprising administration of one or more single agents, either alone or in combination with other therapies for the same disease or condition.

  本发明涉及使用单一药剂，这些药剂是同时靶向两个或更多激酶的化合物，从而大大避免对治疗的抵抗。该发明提供了用于治疗与两个或更多激酶活性相关的各种疾病或病况的方法，包括给予一个或多个单一药剂的给药、管理和治疗，可以单独使用，也可以与其他治疗同一疾病或病况的疗法结合使用。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20020173469A1

  公开（公告）日：2002-11-21

  The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了一种抑制蛋白酶的化合物，包括卡他普星K，以及这些化合物的药物组合物和治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿性关节炎；帕吉特病；恶性高钙血症；以及代谢性骨病，通过向需要治疗的患者投与本发明的化合物来抑制骨量过度流失或过度软骨或基质降解。
• Renal-selective biphenylalkyl 1H-substituted-1, 2, 4- triazole angiotensin I I antagonists for treatment of hypertension
  申请人：G.D. Searle & Co.,

  公开号：US20040220245A1

  公开（公告）日：2004-11-04

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: 1

  本文描述了一种肾选择性化合物，其中，在一种实施例中，这些前药被优先转化为能够阻断血管紧张素II（AII）受体的化合物。这些前药是由两个组分形成的结合物，即由AII拮抗剂化合物提供的第一组分和当两个组分在结合物中化学连接时能够被从第一组分中裂解的第二组分。这两个组分通过一种在肾脏中有选择性的键进行化学连接，例如，通过一种酶。释放的AII拮抗剂化合物随后可用于阻断肾脏内的AII受体。特别感兴趣的结合物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸，5-[[4'-(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基][1,1'-联苯基]-2-基]甲酰肼（如下图所示）是一个例子：1
• Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin
  申请人：G. D. Searle & Co.

  公开号：US05217985A1

  公开（公告）日：1993-06-08

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]]ca rbonylhydrazide, (shown below) is an example: ##STR1##

  本文描述了一种肾选择性化合物，其中，在一个实施例中，这些前药优先转化为能够阻断肾素-血管紧张素系统(AII)受体的化合物。这些前药是由两个组分形成的结合物，即由AII拮抗剂化合物提供的第一组分和当两个组分在结合物中化学连接时能够被裂解的第二组分。这两个组分通过一个键化学连接在一起，该键可以通过肾脏中的酶选择性地裂解。释放的AII拮抗剂化合物然后可用于阻断肾脏内的AII受体。特别感兴趣的结合物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸、5-[[4'-[(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基][1,1'-联苯]-2-基]]羰基肼，（如下所示）是一个例子：##STR1##